News

Genentech, a biotechnology company, and US-based Biogen Idec have announced that a Phase III study of Rituxan plus mycophenolate mofetil and corticosteroids in patients with lupus nephritis did

Philip Stimpson, Mediwatch chief executive commented’ “We are confident that this strategically important distribution agreement will deliver a significant revenue stream. The market for point of care diagnostics

Pfizer has stopped a Phase III clinical trial of Sutent early after the drug showed significant benefit in patients with advanced pancreatic islet cell tumors, also known as

Biothera, a biotechnology company, has received approval form the German regulatory authorities to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGG administered in

Icagen, a biopharmaceutical company, has initiated a Phase II proof-of-concept study of senicapoc, a novel orally available small molecule inhibitor of the KCa3.1 potassium ion channel, in patients

ValiRx, a cancer therapeutics and diagnostics company, has successfully completed its first collaborative stage with Cancer Research Technology, undertaken through the company’s biopharmaceutical division ValiPharma. Trials completed under

Gilead Sciences, a biopharmaceutical company, and CV Therapeutics have signed a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20 per share in cash through

Mediscience Technology, a developer of minimally invasive autofluorescent-based technology for early detection of cancer, has expanded its technology platform with the completion of the acquisition of SensiVida Medical

Financial Data Gross margin stood at 53.4% of net sales, versus 53.2% in 2007, while gross profit amounted to EUR593 million compared with EUR566 million the year before.